Evidence map›Paper›PMID 42105648›Full record

ArticleNeuroImage. Clinical2026

The role of quantitative susceptibility mapping in dementia with Lewy Bodies.

Elettra Capogna, Greta Venturi, Lorenzo Motta, David Neil Manners, Davide Braghittoni, Lucia Guidi, Luca Baldelli, Giovanna Calandra-Buonaura, Luisa Sambati, Annalena Venneri and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NeuroImage. Clinical, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Neuropathological correlates of imaging in dementia with Lewy bodies.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Elettra CapognaFunctional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy.
Greta VenturiFunctional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy.
Lorenzo MottaFunctional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy.
David Neil MannersFunctional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy; Department for Life Quality Studies, University of Bologna, Rimini 47921, Italy.
Davide BraghittoniFunctional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy.
Lucia GuidiFunctional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy.
Luca BaldelliDepartment of Biomedical and Neuromotor Sciences, University of Bologna 40127 Bologna, Italy; U.O.C. Clinica Neurologica Rete Metropolitana (NeuroMet), IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy.
Giovanna Calandra-BuonauraDepartment of Biomedical and Neuromotor Sciences, University of Bologna 40127 Bologna, Italy; U.O.C. Clinica Neurologica Rete Metropolitana (NeuroMet), IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy.
Luisa SambatiU.O.C. Clinica Neurologica Rete Metropolitana (NeuroMet), IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy.
Annalena VenneriDepartment of Medicine and Surgery, University of Parma 43126 Parma, Italy; Department of Neuroscience, University of Sheffield S10 2HQ Sheffield, UK.
Caterina TononFunctional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna 40127 Bologna, Italy.
Micaela MitoloFunctional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy; Department of Medicine and Surgery, University of Parma 43126 Parma, Italy.
Raffaele LodiFunctional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna 40139 Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna 40127 Bologna, Italy. Electronic address: raffaele.lodi@unibo.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron overload has been implicated in the pathology of several neurodegenerative diseases, and quantitative susceptibility mapping (QSM), an MRI-based technique, has identified abnormal iron overload in alpha-synucleinopathies. However, there is a limited understanding of the significance of changes in magnetic susceptibility, assessed by QSM, in patients with Dementia with Lewy Bodies (DLB). In this study, 39 DLB patients (58-88 years) and 30 cognitively unimpaired older adults (OA) (56-86 years) underwent an advanced MRI protocol that included T1w and QSM sequences, and a comprehensive neuropsychological evaluation. This study investigated (1) differences in whole-brain magnetic susceptibility and brain volumes between DLB patients and OA; (2) associations between regional changes in magnetic susceptibility and brain volumes, symptom duration, and cognitive functioning; (3) whether regional changes in magnetic susceptibility could differentiate DLB phenotypes based on earlier symptoms. DLB patients showed higher magnetic susceptibility values than OA in the bilateral substantia nigra, globus pallidus, thalamus, brainstem, and hippocampus, as well as in posterior cortical regions. No significant associations were observed between QSM susceptibility values and brain volumes, symptom duration, or cognitive functions. Using classificatory algorithms, different DLB phenotypes were identified based on iron accumulation values in the basal ganglia, thalamus, brainstem, and frontal cortical regions. Our findings suggest that QSM, assessing in vivo changes in brain iron accumulation, could serve as a useful noninvasive diagnostic biomarker in DLB patients. Longitudinal studies, including the prodromal phase of DLB, are needed to understand the interplay between brain volumetric loss, iron accumulation, and clinical manifestations.

Indexed as

BrainBrain MappingLewy Body DiseaseMagnetic Resonance ImagingAgedAged, 80 and overFemaleHumansMaleMiddle AgedBasal gangliaDementia with Lewy BodiesDLB early phenotypesIron overloadQuantitative susceptibility mappingSubstantia nigra

Identifiers

PMID42105648
PMCPMC13186079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.